The Retinopathy Partnering 2010-2015 report provides understanding and access to the retinopathy partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in retinopathy partnering deals
Top retinopathy deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type
The Retinopathy Partnering 2010-2015 provides understanding and access to the retinopathy partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of retinopathy partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors retinopathy technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
Full Report Details at
This data driven report contains over 35 links to online copies of actual retinopathy deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of retinopathy partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.
Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.
Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
You may also be interested in these related reports:
- Diabetic Retinopathy Global Clinical Trials Review, H1, 2014
- Proliferative Diabetic Retinopathy (PDR) Global Clinical Trials Review, H1, 2014
- Diabetic Retinopathy - Pipeline Review, H2 2014
- Top 50 Big Pharma Partnering and M&A Deal Trends
- Global Cancer Monoclonal Antibody Partnering 2010-2015: Deal Trends, players, financials and forecasts
"Retinopathy Partnering 2010-2015" now available at Fast Market Research
Contact Name: Bill Thompson
Contact Email: firstname.lastname@example.org
Contact Phone: 1-413-485-7001